scorecardresearch
Clear all
Search

COMPANIES

No Data Found

NEWS

No Data Found
Sign in Subscribe
Sputnik V among the safest COVID-19 vaccines: Buenos Aires Health Ministry

Sputnik V among the safest COVID-19 vaccines: Buenos Aires Health Ministry

The study by Buenos Aires Health Ministry demonstrated the Events Supposedly Attributable to Vaccination or Immunisation (ESAVI) after Sputnik V was mostly mild.

Russian COVID-19 vaccine Sputnik V is among the safest COVID-19 vaccines out there, as per a Buenos Aires' Ministry of Health study conducted to monitor the safety of the jab stated. The study found that there were no vaccination-related deaths.

"LATEST NEWS: A #SputnikV shows the safest profile among vaccines against #COVID used in the province of Buenos Aires, Argentina. No recorded vaccination-related deaths- the province's Ministry of Health," Sputnik V tweeted.


"Of the 125 serious ESAVIs reported, none were due to programmatic errors, that is related to the vaccine handling process (such as, for example, incorrect administration or inappropriate use of supplies) and only 6- derived from the application of the three vaccines applied so far in Buenos Aires territory were directly related to the product, generating allergic reactions from which the vaccinated recovered completely. It should be noted that there were no deaths related to the Sputnik V vaccine," Buenos Aires' Health Ministry statement read.

This study was conducted to describe the ESAVI reported to the Integrated Argentine Health Information System (SIISA) since December 29. The campaign date was June 3, 2021. 2.8 million Sputnik V doses were applied, 1.3 million from Sinopharm and 0.9 million Covishield/AstraZeneca doses with a several ESAVI rate per million doses of 0.7, 0.8 and 3.2 respectively.

It demonstrated the Events Supposedly Attributable to Vaccination or Immunisation (ESAVI) was mostly mild. Most commonly reported side effects were fever (47%), headaches (45%), muscle pain and joint pain (39.5%) and pain (46.5%) and swelling (7.4%) in the area where the injection was given. Investigation of ESAVI includes classification as per a series of categories established by the World Health Organisation (WHO) and Pan American Health Organisation (PAHO), Buenos Aires health ministry said in a statement.

Edited by Mehak Agarwal

Also read: WHO forecasts need for annual COVID-19 vaccine booster shots for most vulnerable

Also read: Now, swab samples from phone screens can detect COVID-19

Published on: Jun 25, 2021, 10:47 AM IST
×
Advertisement